At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...

Calquence is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,295 ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

For its part, Regeneron has studies on the go in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) and is also testing odronextamab alongside CD22xCD28 bispecific REGN5837 in aggressive ...

Regeneron has studies of odronextamab on the go in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), and is also testing odronextamab in tandem with a CD22xCD28 bispecific REGN5837 in ...

Clinical-stage CAR T company dosed first patient for Phase 1 trial to evaluate SynKIR™-310, a new drug candidate for relapsed/refractory B cell Non-Hodgkin ...